Article

Nursing Care of Patients Receiving Campath®

Karen Seeley

Elaine S. DeMeyer

biotherapy/targeted therapy
CJON 2002, 6(3), 138-143. DOI: 10.1188/02.CJON.138-143

Monoclonal antibodies are focused therapies with unique in fusion-related complications. Campath® (alemtuzumab, Berlex Laboratories, Richmond, CA) is indicated for the treatment of refractory chronic lymphocytic leukemia and has a complicated administration schedule, severe infusion-related toxicity, and profound immunosuppressive capability. Ambulatory cancer care is challenging simply because of the complex nature of the disease. Management of complicated therapies, such as Campath, stretches resources and requires a coordinated effort by the healthcare team for successful patient outcomes.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.